anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Edoxaban 60 mg + edoxaban 15 mg orally, once daily, at the same time (preferably morning) for up to 12 months, with a 2-4 week follow-up period. If needed when the patient completes or discontinues the study, an open-label transition dose of 30 mg and 15 mg edoxaban tablets will be provided.
PURPOSE: To prepare the subject antigen in high yield without causing significant degradation by carrying out the two-phase extraction of a crushed cell suspension or a cell supernatant with an aqueous solution, then separating the phase containing the antigen and adsorbing the separated antigen on a fumed silica. CONSTITUTION: A polyethylene glycol(PEG) and dextran are added to a crushed cell suspension or a cell supernatant to separate the suspension or supernatant into an upper layer of a PEG-containing layer containing preS2 +S antigen and a dextran-containing layer (lower layer). The separated layers are then centrifuged to take out the upper layer liquid, which is diluted and the filtered. The resultant filtrate is concentrated to remove the PEG by ultrafiltration. The pH is slightly raised and the temperature is reduced to adsorb the antigen on a fumed silica. The antigen is subsequently extracted from the fumed silica to perform the removal of the residual silica, concentrating, diafiltration (preferably with a boric acid buffer solution and sterile filtration to afford the preS2 +S antigen.
Patients on long-term immunosuppressive and/or immunomodulating medication may be susceptible to serious COVID-19. Hence, it is important they get sufficient protection by a COVID-19 vaccine. However, these patients may also be at risk for a less robust vaccine response. There is an urgent need to assess the humoral and cellular immune response to COVID-19 vaccines in these patient groups. The clinical consequences could be to administer several re-vaccinations or to adjust medication. This prospective, observational study aims to assess the immune response after COVID vaccination in patients suffering from inflammatory diseases and using immunosuppressive medication. Also, liver transplanted patients on immunosuppressive medication will be included.

Serum and whole blood samples will be obtained from all participants before and 1-4 weeks after the vaccination. Additionally, serum samples will be collected every 3-6 months for 5 years. If patients are allotted further vaccine doses , the patient response will be assessed by blood tests 2-4 weeks after any additional vaccine doses. In a subset of patients, samples will be drawn to study cellular immune responses. Demographic data and data regarding immunosuppressive medication will be recorded. Disease activity (clinical activity indices and biomarkers of inflammation) will be assessed. Blood samples will be obtained for biobank. Information regarding vaccination status and potential COVID-19 testing will be obtained from relevant registers.
BACKGROUND: The majority of adolescents undergoing surgery report unused prescription opioids after surgery, increasing the risk of diversion, misuse, and addiction. Adult studies have demonstrated that opioid use 24 hours before discharge corresponds with opioid use at home. We hypothesized that inpatient opioid consumption is associated with outpatient opioid use in adolescents.
METHODS: Adolescents aged 13-20 years undergoing elective surgery associated with an opioid prescription were prospectively recruited. Parent-adolescent dyads were surveyed preoperatively to assess sociodemographics, health literacy, and baseline substance use, and opioid use was measured at 30- and 90-days postoperatively. Medical records were reviewed to calculate cumulative opioid use during hospitalization. Inpatient and postoperative opioid use was converted to oral morphine equivalents. Adjusting for age, sex, race, health literacy, alcohol use, pain score, and surgery, multivariable linear regression identified factors associated with outpatient oral morphine equivalent use 90 days postoperatively.
RESULTS: Overall, 103 adolescents were enrolled. Median oral morphine equivalents used from 24 and 48 hours before discharge and throughout the hospitalization were 30.8 (interquartile range:11.7-45.0), 67.5 (interquartile range:37.5-94.3), and 97.5 (interquartile range:18.0-152.7), respectively. Regression analysis demonstrated that adolescent-reported pain at discharge (P = .028) and cumulative oral morphine equivalents used 24 hours (P < .001) and 48 hours (P = .003) before discharge were significantly associated with postoperative oral morphine equivalents use at home. Oral morphine equivalents consumption 24 hours before discharge estimated cumulative oral morphine equivalents use 90 days postoperatively at a 1-to-5 ratio in 94.1% of patients.
CONCLUSION: For adolescents undergoing surgery, patient-reported pain at discharge and oral morphine equivalents administered 24 hours before discharge are associated with cumulative outpatient opioid use. Tailoring outpatient prescriptions to total oral morphine equivalent consumption 24 hours before discharge could reduce excess opioid prescribing.
PROBLEM TO BE SOLVED: To obtain a dental composite material excellent in smooth lubricating properties and bending strength, and having a color tone adaptability to a natural tooth by blending a polymerizable monomer with two different at specific ratios, and further prescribing the degree of diffusion of a transmitted light within a specific region. SOLUTION: This dental composite material consists of (a) 100 pts.wt. polymerizable monomer, (b) 200-300 pts.wt. filler (this filler has <=0.06 difference in refractive index from that of a matrix after curing the composition, and is obtained by heat-treating an inorganic filler having 0.01-1μm mean particle diameter after aggregating the same) and (c) 5-100 pts.wt. inorganic filler (this filler has >=0.06 difference in refractive index from that of the matrix after curing the composition and having >=1μm mean particle diameter), and is prescribed to have 0.002-0.3 degree of diffusion D expressed by the formula (I is an intensity of a transmitted light; I0 , I20 , I70 are each an intensity of light in the directions of 0 deg., 20 deg. and 70 deg. to a direction perpendicular to a specimen plate) of the transmitted light.  A fine inorganic filler having <=0.1μm is preferably added by 10-70 pts.wt. into this system.
Since chemotherapy remains one of the primary treatment modalities for gynecologic malignancies, there is increasing interest in non-pharmacological methods of reducing chemotherapy side effects in cancer patients. Our goal is to increase the knowledge surrounding lifestyle modifications, specifically the fasting mimicking diet, on chemotherapy-related side effects, which may be more acceptable to patients than a previously studied water-only fasting diet. To expand this knowledge, The investigators will focus on patients undergoing chemotherapy for gynecologic malignancies. These patients will be assigned to no dietary restriction (control group) or a 5-day fasting mimicking diet (FMD by L-Nutra) for three days prior to, the day of, and one day following chemotherapy treatments (treatment group). The investigators aim to evaluate the feasibility of a fasting mimicking diet in addition to its metabolic effects on the body, patient reported side effects, patient quality of life, deviations or delays in treatment plans, and hospital admissions. Our hypothesis is that a fasting mimicking diet will significantly decrease chemotherapy-related side effects while providing good quality of life.
Dopamine Hydrochloride in 5% Dextrose Injection, USP is a sterile, nonpyrogenic, prediluted solution of dopamine hydrochloride in 5% dextrose injection. It is administered by intravenous infusion.

Each 100 mL contains dopamine hydrochloride 80 mg (0.8 mg/mL), 160 mg (1.6 mg/mL) or 320 mg (3.2 mg/mL) and dextrose, hydrous 5 g in water for injection, with sodium metabisulfite added 50 mg as a stabilizer; osmolar concentration, respectively 261, 269, or 286 mOsmol/liter (calc.), pH 3.8 (2.5 to 4.5). May contain hydrochloric acid and/or sodium hydroxide for pH adjustment.

Dopamine administered intravenously is a myocardial inotropic agent, which also may increase mesenteric and renal blood flow plus urinary output.

Dopamine Hydrochloride is chemically designated 3, 4-dihydroxyphenethylamine hydrochloride (C8H11NO2 • HCl), a white crystalline powder freely soluble in water. It has the following structural formula:

Dopamine (also referred to as 3-hydroxytyramine) is a naturally occurring endogenous catecholamine precursor of norepinephrine.

Dextrose, USP is chemically designated D-glucose monohydrate (C6H12O6 • H2O), a hexose sugar freely soluble in water. It has the following structural formula:

Water for Injection, USP is chemically designated H2O.

The flexible plastic container is fabricated from a specially formulated CR3 plastic material. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period.
PURPOSE:A hair cosmetic having excellent promoting action on hair growth free from side effect, comprising minoxidil (2,4-diamino-6-piperidinopyrimidine-3-oxide) as a nourishing component. CONSTITUTION:A hair tonic cosmetic obtained by dissolving 1-10g minoxidil in 1l solution prepared by adding perfume, an oily wetting agent, a refreshing agent, a hair stimulating agent, etc. to a solvent such as an alcohol, water, etc. A hair lotion type is most effective as the type of the use of this cosmetic, and the cosmetic may be used as a hairdressing such as hair cream, pomade, etc. Minoxidil is used as an oral hypotensor and has no side effect such as flare, anthema, etc. caused by application at all.
Adults with a histological, clinical or radiological diagnosis of cirrhosis who are admitted to RIE over a 4-month period will be approached by a member of their clinical care team for potential participation. Eligible patients may be recruited from accident and emergency, the acute medical unit, hepatology ward, high dependency or intensive care units. Recurrent admissions are common, so only the first admission for each recruited patient will be included. Patients will be monitored to identify acute kidney injury (AKI) during admission.
According to an embodiment of the present invention, provided is a novel specified Streptomyces sp. strain isolated from soil and a use thereof. According to an embodiment of the present invention, various whitening effect materials, produced by the specified Streptomyces sp. strain, prevent the generation of melanin or inhibit activity of tyrosinase, and have a more profound effect than arbutin, a commercially available and effective whitening material. Therefore, according to an embodiment of the present invention, the specified Streptomyces sp. strain, a culture medium of the specified Streptomyces sp. strain, or a culture medium extract of the specified Streptomyces sp. strain can be used as an active ingredient of a whitening composition.
<P>PROBLEM TO BE SOLVED: To provide an external plaster in which the occurrence of eruption is reduced extremely, and in which the medicament itself has little skin irritation.  <P>SOLUTION: The plaster comprises an adhesive base and a supporter. The adhesive base contains 3-30 mass% low molecular-weight polyisobutylene, and aluminum hydroxide and/or titanium oxide and is substantially free from water. A skin irritation-ameliorating agent therefor is also provided. Preferably, the adhesive base further contains the aluminum hydroxide and/or the titanium oxide in the plaster comprising the adhesive base containing a thermoplastic rubber and the low molecular-weight polyisobutylene and is substantially free from the water, and the supporter. The skin irritation-ameliorating agent therefor is also provided.  <P>COPYRIGHT: (C)2007,JPO&INPIT
<P>PROBLEM TO BE SOLVED: To obtain a bleaching or chapped skin-preventing agent which has excellent bleaching and chapped skin-preventing effects and is not deteriorated in preparations, and to provide a skin care preparation for external use which contains the bleaching or chapped skin-preventing agent, is used for the skin and has the temporally stabilized bleaching and chapped skin-preventing effects.  <P>SOLUTION: The agent contains as an active ingredient a liquid [an aqueous solution of the seed kernel of Coixlachryma-jobi L. or Coix lachryma-jobi L. var. ma-yuen (Romam)] obtained by steam-distilling an extract obtained by extracting the seed kernel of Coixlachryma-jobi L. or Coix lachryma-jobi L. var. ma-yuen (Romam) with water. The chapped skin-preventing agent contains the above liquid as an active ingredient. The skin care preparation for external use comprises the above liquid and one or more specific pharmaceutically effective compounds such as ascorbic acid, glycyrrhizic acid, their derivatives and their salts.  <P>COPYRIGHT: (C)2004,JPO
MBQR is an online, Zoom-based mindfulness course that meets 2.5 hour per week for ten weeks, facilitated by queer mindfulness teachers, with weekly home practice and additional reflection and reading activities that can be completed by participants independently via study website portal. In addition to the 10 weekly sessions there is an all-day retreat (6hrs) that takes place around week 6. The participants also meet one-on-one with the instructor(s) at the beginning and middle of class for a 30-minute welcome call and check in.
The present invention provides a method for processing and blending Lagenaria siceraria powder and food thereof. Pre-mature fresh Lagenaria siceraria is sliced by a slicing machine or slivered by a slivering machine to become broken Lagenaria siceraria flesh, the broken Lagenaria siceraria flesh is dried in the sun or shade under the condition of indoor ventilation to obtain a dried Lagenaria siceraria raw material, the dried Lagenaria siceraria raw material is put into a pulverizer, pulverized into powder and sifted through a 200-mesh sieve, the sifted powder is taken as Lagenaria siceraria raw material powder, 100 kilograms of the Lagenaria siceraria raw material powder, 10 kilograms of mung bean powder and 10 kilograms of glutinous rice powder are mixed to obtain Lagenaria siceraria powder. The Lagenaria siceraria powder is used to prepare dough wrappers, fillings, noodles, biscuits, auxiliary medicaments, nutritional agents, anti-cancer agents and sauce. By using the method provided by the invention, the fresh Lagenaria siceraria is processed into the raw material powder and then added to the food, which not only maintains nutritional components of the Lagenaria siceraria, but also provides a special taste of the Lagenaria siceraria. The Lagenaria siceraria powder and food made from the Lagenaria siceraria powder have advantages of comprehensive nutrition and wide application. The method is suitable for being applied to processing of the Lagenaria siceraria powder and food.
FIELD: chemistry; biochemistry. ^ SUBSTANCE: invention relates to biotechnology, virology and medicine. Vaccines can be used to treat individuals chronically infected with HIV by inducing a protective cell-mediated response in these individuals against the same HIV subtype which was used to make the vaccine. Invention can be used in medicine. ^ EFFECT: obtaining an intact human immunodeficiency virus of a defined subtype which can be used in making vaccines and pharmaceutical compositions containing such vaccines. ^ 21 cl, 2 dwg, 4 ex
BACKGROUND: Antagonists of glycoprotein VI-triggered platelet activation used in combination with recanalisation therapies are a promising therapeutic approach in acute ischaemic stroke. Glenzocimab is an antibody fragment that inhibits the action of platelet glycoprotein VI. We aimed to determine and assess the safety and efficacy of the optimal dose of glenzocimab in patients with acute ischaemic stroke eligible to receive alteplase with or without mechanical thrombectomy.
METHODS: This randomised, double-blind, placebo-controlled study with dose-escalation (1b) and dose-confirmation (2a) phases (ACTIMIS) was done in 26 stroke centres in six European countries. Participants were adults (≥18 years) with disabling acute ischaemic stroke with a National Institutes of Health Stroke Scale score of 6 or higher before alteplase administration. Patients were randomly assigned treatment using a central electronic procedure. Total administered dose at the end of the intravenous administration was 125 mg, 250 mg, 500 mg, and 1000 mg of glenzocimab or placebo in phase 1b and 1000 mg of glenzocimab or placebo in phase 2a. Treatment was initiated 4·5 h or earlier from stroke symptom onset in patients treated with alteplase with or without mechanical thrombectomy. The sponsor, study investigator and study staff, patients, and central laboratories were all masked to study treatment until database lock. Primary endpoints across both phases were safety, mortality, and intracranial haemorrhage (symptomatic, total, and fatal), assessed in all patients who received at least a partial dose of study medication (safety set). The trial is registered on ClinicalTrials.gov, NCT03803007, and is complete.
FINDINGS: Between March 6, 2019, and June 27, 2021, 60 recruited patients were randomly assigned to 125 mg, 250 mg, 500 mg, or 1000 mg glenzocimab, or to placebo in phase 1b (n=12 per group) and were included in the safety analysis. Glenzocimab 1000 mg was well tolerated and selected as the phase 2a recommended dose; from Oct 2, 2020, to June 27, 2021, 106 patients were randomly assigned to glenzocimab 1000 mg (n=53) or placebo (n=53). One patient in the placebo group received glenzocimab in error and therefore 54 and 52, respectively, were included in the safety set. In phase 2a, the most frequent treatment-emergent adverse event was non-symptomatic haemorrhagic transformation, which occurred in 17 (31%) of 54 patients treated with glenzocimab and 26 (50%) of 52 patients treated with placebo. Symptomatic intracranial haemorrhage occurred in no patients treated with glenzocimab compared with five (10%) patients in the placebo group. All-cause deaths were lower with glenzocimab 1000 mg (four [7%] patients) than with placebo (11 [21%] patients).
INTERPRETATION: Glenzocimab 1000 mg in addition to alteplase, with or without mechanical thrombectomy, was well tolerated, and might reduce serious adverse events, intracranial haemorrhage, and mortality. These findings support the need for future research into the potential therapeutic inhibition of glycoprotein VI with glenzocimab plus alteplase in patients with acute ischaemic stroke.
FUNDING: Acticor Biotech.
Lyophilized S95014 reconstituted will provide 5 mL of extractable volume with the concentration of 750 U/mL. The vial of lyophilized powder (3.750 U/vial) is reconstituted with 5.2 mL of Sterile Water for Injection to obtain a 750 U/mL solution for single use.
The present invention discloses oral liquid for treating lung cancer and intestinal cancer and a preparation method thereof. The oral liquid is prepared by decocting traditional Chinese medicine components with water to obtain medicine liquid. The oral liquid has the main following traditional Chinese medicine components: long-noded pit viper straw, arisaema tuber, field pennycress, semen coicis, raw gardenia, wine rhubarb, raw rhubarb, elaphe climacophora schlegel, peach kernel, astragalus root and tortoise plastron. The oral liquid has the advantages of reasonable composition, good integral treatment effect, safety, no side effect and no side reaction, which enables patients to be stably treated. The oral liquid is mainly used for preventing and treating lung cancer and intestinal cancer, and also has certain treating effect on stomack cancer. The preparation method of the oral liquid has the advantages of simple and easy operation, unique, scientific and reasonable technology and easy popularization.
NEW MATERIAL:A compound shown by formula I (R<1> and R<2> are methyl or ethyl; steric configuration of 1,2-diaminocyclohexane is cis-, trans-l or trans-d- or trans-dl-). EXAMPLE:(trans-dl-1,2-Diaminocylcohexane)dimethylmalonatoplatinum (II). USE:An antitumor agent. PREPARATION:An aqueous solution of potassium chloroplatinate is treated with potassium iodide to give an aqueous solution of potassium chloroplatinate iodide, which is reacted with 1,2-diaminocyclohexane to give a compound shown by formula II. Then the compound shown by formula II is treated with silver nitrate in an aqueous solution to give a dinitratoacetic acid shown by formula III. Further the compound shown by formula III is reacted with a desired dicarboxylic acid.
Optimal pain relief in day-case surgery is imperative to patient comfort and timely discharge from hospital. Short-acting opioids are commonly used for analgesia in modern anaesthesia, allowing rapid recovery after surgery. Plasma concentration fluctuations from repeated dosing of short-acting opioids can cause patients to oscillate between analgesia with potential adverse effects, and inadequate analgesia requiring rescue dosing. Methadone's unique pharmacology may offer effective and sustained analgesia with less opioid consumption, potentially reducing adverse effects. Using a double-blind, randomised controlled trial, we compared post-anaesthesia care unit opioid consumption between day-case gynaecological laparoscopy patients who received either intravenous methadone (10 mg), or short-acting opioids intraoperatively. The primary outcome was post-anaesthesia care unit opioid consumption in oral morphine equivalents. Secondary outcomes included total opioid consumption, discharge opioid consumption, pain scores (0-10) until discharge, adverse effects (respiratory depression, postoperative nausea and vomiting, excess sedation), and rate of admission. Seventy patients were randomly assigned. Patients who received methadone consumed on average 9.44 mg fewer oral morphine equivalents in the post-anaesthesia care unit than the short-acting group (18.02 mg vs 27.46 mg, respectively, 95% confidence interval 0.003 to 18.88, P = 0.050) and experienced lower postoperative pain scores at every time point, although absolute differences were small. There was no evidence of lower hospital or discharge opioid consumption. No significant differences between the methadone and short-acting groups in other outcomes were identified: respiratory depression 41.2% versus 31.4%, Padjusted >0.99; postoperative nausea and vomiting 29.4% versus 42.9%, Padjusted >0.99; overnight admission 17.7% versus 11.4%, Padjusted >0.99; excess sedation 8.82% versus 8.57%, Padjusted >0.99. This study provides evidence that, although modestly, methadone can reduce post-anaesthesia care unit opioid consumption and postoperative pain scores after day-case gynaecological laparoscopy. There were no significant differences in any secondary outcomes.